Attitudes toward a future norovirus vaccine among members of an integrated healthcare delivery system in Portland, Oregon, 2016-2017

References

• Hall AJ, Lopman BA, Payne DC, Patel MM, Gastañaduy PA, Vinjé J, Parashar UD. Norovirus disease in the United States. Emerg Infect Dis. 2013 Aug;19(8):1198–8. doi:10.3201/eid1908.130465.
   PubMed Web of Science ®Google Scholar
• Burke RM, Mattison CP, Pindyck T, Dahl RM, Rudd J, Bi D, Curns AT, Parashar U, Hall AJ. Burden of norovirus in the United States, as estimated based on administrative data: updates for medically attended illness and mortality, 2001–2015. Clin Infect Dis. 2021 Jul 1;73(1):1–8. doi:10.1093/cid/ciaa438.
   PubMed Web of Science ®Google Scholar
• Steimle LN, Havumaki J, Eisenberg MC, Eisenberg JNS, Prosser LA, Pike J, Ortega-Sanchez IR, Mattison CP, Hall AJ, Steele MK, et al. Cost-effectiveness of pediatric norovirus vaccination in daycare settings. Vaccine. 2021 Apr 8;39(15):2133–2145. doi:10.1016/j.vaccine.2021.02.066.
   PubMed Web of Science ®Google Scholar
• Treanor J, Sherwood J, Cramer JP, Le Cam Bouveret N, Lin S, Baehner F, Borkowski A. A phase 2 study of the bivalent VLP norovirus vaccine candidate in older adults; impact of MPL adjuvant or a second dose. Vaccine. 2020 Aug 10;38(36):5842–50. doi:10.1016/j.vaccine.2020.06.011.
   PubMed Web of Science ®Google Scholar
• Sherwood J, Mendelman PM, Lloyd E, Liu M, Boslego J, Borkowski A, Jackson A, Faix D. Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults. Vaccine. 2020 Sep 22;38(41):6442–9. doi:10.1016/j.vaccine.2020.07.069.
   PubMed Web of Science ®Google Scholar
• Vaxart announces positive preliminary topline data from dose-ranging phase 2 study of its bivalent norovirus vaccine candidate; 2023 [accessed 2023 Jul 6]. https://www.globenewswire.com/news-release/2023/07/06/2700292/25416/en/Vaxart-Announces-Positive-Preliminary-Topline-Data-from-Dose-Ranging-Phase-2-Study-of-its-Bivalent-Norovirus-Vaccine-Candidate.html.
   Google Scholar
• Lopez P, Lopez-Medina E, Saez-Llorens X, deAntonio R, Masuda T, Mendelman PM, Sherwood J, Baehner F, Borkowski A. Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: a phase 2 randomized, double-blind trial. Hum Vaccin Immunother. 2023 Dec 31;19(1):2204787. doi:10.1080/21645515.2023.2204787.
   PubMed Web of Science ®Google Scholar
• Olson D, Krager S, Lamb MM, Rick AM, Asturias EJ. Knowledge of norovirus and attitudes toward a potential norovirus vaccine in rural Guatemala: a cross-sectional exploratory survey. Am J Trop Med Hyg. 2018 May;98(5):1498–1501. doi:10.4269/ajtmh.17-0771.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Saez-Llorens X, Blazevic V, Lopez P, Lopez E, Masuda T, Mendelman PM, Liu M, Sherwood J, Baehner F, et al. Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8 years of age: a phase 2 randomized, double-blind study. Vaccine. 2022 Jun 9;40(26):3588–3596. doi:10.1016/j.vaccine.2022.04.089.
   PubMed Web of Science ®Google Scholar
• Biospace. Vaxart doses first subject in the phase 2 clinical trial of its bivalents norovirus candidate; [ accessed 2023 May 11]. https://www.biospace.com/article/releases/vaxart-doses-first-subject-in-the-phase-2-clinical-trial-of-its-bivalent-norovirus-candidate/.
   Google Scholar
• Schmidt MA, Groom HC, Rawlings AM, Mattison CP, Salas SB, Burke RM, Hallowell BD, Calderwood LE, Donald J, Balachandran N, et al. Incidence, etiology, and healthcare utilization for acute gastroenteritis in the community, United States. Emerg Infect Dis. 2022 Nov;28(11):2234–2242. doi:10.3201/eid2811.220247.
   PubMed Web of Science ®Google Scholar
• Leuchter RK, Jackson NJ, Mafi JN, Sarkisian CA. Association between covid-19 vaccination and influenza vaccination rates. N Engl J Med. 2022 Jun 30;386(26):2531–2532. doi:10.1056/NEJMc2204560.
   PubMed Web of Science ®Google Scholar
• Soorapanth S, Cheung R, Zhang X, Mokdad AH, Mensah GA. Rural–urban differences in vaccination and hesitancy rates and trust: US COVID-19 trends and impact survey on a social media platform, May 2021–April 2022. Am J Public Health. 2023 Apr 13;113(6):1–9. doi:10.2105/AJPH.2023.307274.
   PubMedGoogle Scholar
• Services MDoHaH. Prioritization of hepatitis a vaccination for food handlers and healthcare workers in responseto the hepatitis a outbreak in michigan: frequently asked questions; 2023 Oct 27 [accessed 2023 Oct 27]. https://www.michigan.gov/-/media/Project/Websites/mdhhs/Folder3/Folder35/Folder2/Folder135/Folder1/Folder235/FAQ_-_Vaccination_Prioritizing_for_Food_Handlers_and_Healthcare_Workers_11-3-17.pdf?rev=9ab290266cfe41b7824e70d41ab9f1b8.
   Google Scholar
• Gallant AJ, Nicholls LAB, Rasmussen S, Cogan N, Young D, Williams L, Gesser-Edelsburg A. Changes in attitudes to vaccination as a result of the COVID-19 pandemic: a longitudinal study of older adults in the UK. PLoS One. 2021;16(12):e0261844. doi:10.1371/journal.pone.0261844.
   PubMed Web of Science ®Google Scholar
• Lee Mortensen G, Harrod-Lui K. Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies. Expert Rev Vaccines. 2022 Oct;21(10):1523–1531. doi:10.1080/14760584.2022.2108799.
   PubMed Web of Science ®Google Scholar
• Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, Sánchez PJ, Kotton CN, Mahon BE, Meyer S, Long SS, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the advisory committee on immunization practices – United States, 2023. Morb Mortal Wkly Rep. 2023 Aug 25;72(34):920–5. doi:10.15585/mmwr.mm7234a4.
   PubMed Web of Science ®Google Scholar
• Burke RM, Mattison CP, Marsh Z, Shioda K, Donald J, Salas SB, Naleway AL, Biggs C, Schmidt MA, Hall AJ, et al. Norovirus and other viral causes of medically attended acute gastroenteritis across the age spectrum: results from the medically attended acute gastroenteritis study in the United States. Clin Infect Dis. 2021 Aug 16;73(4):e913–e920. doi:10.1093/cid/ciab033.
   PubMed Web of Science ®Google Scholar
• Aliabadi N, Tate JE, Haynes AK, Parashar UD. Centers for disease C, prevention. Sustained decrease in laboratory detection of rotavirus after implementation of routine vaccination-United States, 2000-2014. Morb Mortal Wkly Rep. 2015 Apr 10;64(13):337–42.
   PubMed Web of Science ®Google Scholar
• Getachew HB, Dahl RM, Lopman BA, Parashar UD. Rotavirus vaccines and health care utilization for diarrhea in US children, 2001 to 2015. Pediatr Infect Dis J. 2018 Sep;37(9):943–948. doi:10.1097/INF.0000000000001988.
   PubMed Web of Science ®Google Scholar